Defense mechanisms of the respiratory system and aerosol production systems

Medicinal Chemistry

Volumn 10, Issue 2, 2014, Pages 123-136

  Zarogoulidis, Paul ^a,b   Darwiche, Kaid ^b   Yarmus, Lonny ^c   Spyratos, Dionysios ^a   Secen, Nevena ^d   Hohenforst Schmidt, Wolfgang ^e   Katsikogiannis, Nikolaos ^f   Huang, Haidong ^h   Gschwendtner, Andreas ^g   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF NOVI SAD   (Serbia)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^g Pathology Department Clinic of Amberg   (Germany)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Aerosol; Defense mechanisms; Dry powder; Inhalers; Respiratory system

Indexed keywords

FLUTICASONE; IMMUNOGLOBULIN; SALBUTAMOL; SALMETEROL; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TIOTROPIUM BROMIDE; ANTIINFECTIVE AGENT; INSULIN;

AEROSOL; ARTICLE; BIOEQUIVALENCE; BREATHING RATE; DEFENSE MECHANISM; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRY POWDER INHALER; HUMAN; IMMUNITY; IONIC STRENGTH; JET NEBULIZER; LOWER RESPIRATORY TRACT; LUNG ALVEOLUS MACROPHAGE; LYMPH FLOW; MEDICAL NEBULIZER; METERED DOSE INHALER; NATURAL KILLER CELL; NEBULIZER; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RESPIRATORY THERAPEUTIC DEVICE; RESPIRATORY TRACT INFLAMMATION; SOFT MIST INHALER; SURFACE TENSION; TIDAL VOLUME; ULTRASONIC NEBULIZER; UPPER RESPIRATORY TRACT; VISCOSITY; DRUG EFFECTS; GENE THERAPY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG NEOPLASMS; RESPIRATORY FUNCTION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; GENETIC THERAPY; HUMANS; INSULIN; LUNG NEOPLASMS; RESPIRATORY PHYSIOLOGICAL PHENOMENA; RESPIRATORY SYSTEM;

EID: 84898747536     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340641130900041     Document Type: Article

References (106)

1. Newman, S.P. Aerosol deposition considerations in inhalation therapy. Chest, 1985, 88, (2 Suppl), 152S-160S. (Pubitemid 16246728)
2. Phipps, P.R.; Gonda, I.; Anderson, S.D.; Bailey, D.; Bautovich, G. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur. Respir. J., 1994, 7(8), 1474-1482. (Pubitemid 24268335)
3. Swift, D.L. Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols. Am. Rev. Respir Dis., 1980, 122(5 Pt 2), 71-77. (Pubitemid 11172649)
4. Densmore, C.L. The re-emergence of aerosol gene delivery: a viable approach to lung cancer therapy. Curr. Cancer Drug Targets, 2003, 3(4), 275-286. (Pubitemid 36944261)
5. Labiris, N.R.; Dolovich, M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56(6), 588-599. (Pubitemid 37491710)
6. Cryan, S.A. Carrier-based strategies for targeting protein and pep-tide drugs to the lungs. Aaps J., 2005, 7(1), E20-41.
7. Summers, Q.A. Inhaled drugs and the lung. Clin. Exp. Allergy, 1991, 21(3), 259-268.
8. Folkesson, H.G.; Matthay, M.A.; Westrom, B.R.; Kim, K.J.; Karls-son, B.W.; Hastings, R.H. Alveolar epithelial clearance of protein. J. Appl. Physiol., 1996, 80(5), 1431-1445. (Pubitemid 26143889)
9. Martonen, T.B. Mathematical model for the selective deposition of inhaled pharmaceuticals. J. Pharm. Sci., 1993, 82(12), 1191-1199. (Pubitemid 23354135)
10. Tatsumura, T.; Koyama, S.; Tsujimoto, M.; Kitagawa, M.; Ka-gamimori, S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br. J. Cancer, 1993, 68(6), 1146-1149. (Pubitemid 23356667)
11. Tatsumura, T.; Yamamoto, K.; Murakami, A.; Tsuda, M.; Sugi-yama, S. [New chemotherapeutic method for the treatment of tracheal and bronchial cancers-nebulization chemotherapy]. Gan. No. Rinsho., 1983, 29(7), 765-770.
12. Effros, R.M.; Mason, G.R. Measurements of pulmonary epithelial permeability in vivo. Am. Rev. Respir. Dis., 1983, 127(5 Pt 2), S59-65. (Pubitemid 13103650)
13. Bosquillon, C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci., 2010, 99(5), 2240-2255.
14. Tseng, C.L.; Su, W.Y.; Yen, K.C.; Yang, K.C.; Lin, F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials, 2009, 30(20), 3476-3485.
15. Cai, L.; Wang, X.; Wang, W.; Qiu, N.; Wen, J.; Duan, X.; Li, X.; Chen, X.; Yang, L.; Qian, Z.; Wei, Y.; Chen, L. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overex-pressing tumor in vivo. Int. J. Nanomedicine, 2012, 7, 4499-4510.
16. Freitag, L.; Bremme, J.; Schroer, M. High frequency oscillation for respiratory physiotherapy. Br. J. Anaesth., 1989, 63(7 Suppl 1), 44S-46S. (Pubitemid 20020028)
17. Freitag, L.; Schroer, M.; Bremme, J. High frequency oscillators with adjustable waveforms: practical aspects. Br. J. Anaesth., 1989, 63(7 Suppl 1), 38S-43S. (Pubitemid 20020027)
18. Houtmeyers, E.; Gosselink, R.; Gayan-Ramirez, G.; Decramer, M. Regulation of mucociliary clearance in health and disease. Eur. Respir. J., 1999, 13(5), 1177-1188. (Pubitemid 29288948)
19. Satir, P.; Sleigh, M.A. The physiology of cilia and mucociliary interactions. Annu Rev. Physiol., 1990, 52, 137-155. (Pubitemid 20103531)
20. Janeway, C.A., Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today, 1992, 13(1), 11-16.
21. Medzhitov, R.; Janeway, C.A., Jr. On the semantics of immune recognition. Res. Immunol., 1996, 147(4), 208-214. (Pubitemid 26349049)
22. Scott, P.; Trinchieri, G. The role of natural killer cells in hostparasite interactions. Curr. Opin. Immunol., 1995, 7(1), 34-40.
23. Sibille, Y.; Reynolds, H.Y. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am. Rev. Respir. Dis., 1990, 141(2), 471-501. (Pubitemid 20068893)
24. Thepen, T.; Kraal, G.; Holt, P.G. The role of alveolar macrophages in regulation of lung inflammation. Ann. N. Y. Acad. Sci., 1994, 725, 200-206. (Pubitemid 24222048)
25. Ulevitch, R.J.; Tobias, P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol., 1995, 13, 437-457.
26. Keane, M.P.; Standiford, T.J.; Strieter, R.M. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. Eur. Respir. J., 1997, 10(6), 1199-1202. (Pubitemid 27278232)
27. Keane, M.P.; Arenberg, D.A.; Lynch, J.P., 3rd; Whyte, R.I.; Iannet-toni, M.D.; Burdick, M.D.; Wilke, C.A.; Morris, S.B.; Glass, M.C.; DiGiovine, B.; Kunkel, S.L.; Strieter, R.M. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol., 1997, 159(3), 1437-1443. (Pubitemid 127484123)
28. Lukacs, N.W.; Chensue, S.W.; Karpus, W.J.; Lincoln, P.; Keefer, C.; Strieter, R.M.; Kunkel, S.L. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am. J. Pathol., 1997, 150(5), 1861-1868. (Pubitemid 27193831)
29. Fearon, D.T.; Locksley, R.M. The instructive role of innate immunity in the acquired immune response. Science, 1996, 272(5258), 50-53.
30. Cella, M.; Sallusto, F.; Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 1997, 9(1), 10-16. (Pubitemid 27095893)
31. Seder, R.A.; Paul, W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol., 1994, 12, 635-673. (Pubitemid 24140427)
32. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 1995, 13, 251-276.
33. Haas, W.; Pereira, P.; Tonegawa, S. Gamma/delta cells. Annu. Rev. Immunol., 1993, 11, 637-685. (Pubitemid 23115020)
34. Moreira, A.L.; Wang, J.; Tsenova-Berkova, L.; Hellmann, W.; Freedman, V.H.; Kaplan, G. Sequestration of Mycobacterium tuberculosis in tight vacuoles in vivo in lung macrophages of mice infected by the respiratory route. Infect. Immun., 1997, 65(1), 305-308. (Pubitemid 27008938)
35. Berman, P.R.; Schuller, F.; Nienhuis, G. Generation of magnetic-state polarization in light-induced collisional energy transfer: Weak-field, quasistatic-wing limit. Phys. Rev. A., 1990, 42(1), 459-473.
36. Noelle, R.J. CD40 and its ligand in host defense. Immunity, 1996, 4(5), 415-419. (Pubitemid 26354651)
37. Reynolds, H.Y: Immunologic system in the respiratory tract. Physiol. Rev., 1991, 71(4), 1117-1133.
38. Weber, A.; Morlin, G.; Cohen, M.; Williams-Warren, J.; Ramsey, B.; Smith, A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr. Pulmonol., 1997, 23(4), 249-260. (Pubitemid 27185033)
39. Eschenbacher, W.L.; Boushey, H.A.; Sheppard, D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis., 1984, 129(2), 211-215. (Pubitemid 14189156)
40. Darquenne, C. Aerosol deposition in health and disease. J. Aerosol Med. Pulm. Drug Deliv., 2012, 25(3), 140-147.
41. Jin, H.H.; Fan, J.R.; Zeng, M.J.; Cen.; K.F. Large eddy simulation of inhaled particle deposition within the human upper respiratory tract. J. Aerosol Sci., 2007, 38(3), 257-268. (Pubitemid 46365707)
42. Gautam, A.; Densmore, C.L.; Golunski, E.; Xu, B.; Waldrep, J.C. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol. Ther., 2001, 3(4), 551-556. (Pubitemid 32509849)
43. Densmore, C.L.; Kleinerman, E.S.; Gautam, A.; Jia, S.F.; Xu, B.; Worth, L.L.; Waldrep, J.C.; Fung, Y.K.; T'Ang, A.; Knight, V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther., 2001, 8(9), 619-627. (Pubitemid 32912235)
44. Koshkina, N.V.; Agoulnik, I.Y.; Melton, S.L.; Densmore, C.L.; Knight, V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol. Ther., 2003, 8(2), 249-254. (Pubitemid 37062835)
45. Davies, L.A.; McLachlan, G.; Sumner-Jones, S.G.; Ferguson, D.; Baker, A.; Tennant, P.; Gordon, C.; Vrettou, C.; Baker, E.; Zhu, J.; Alton, E.W.; Collie, D.D.; Porteous, D.J.; Hyde, S.C.; Gill, D.R. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol. Ther., 2008, 16(7), 1283-1290. (Pubitemid 351866060)
46. Gautam, A.; Waldrep, J.C.; Kleinerman, E.S.; Xu, B.; Fung, Y.K.; T'Ang, A.; Densmore, C.L. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods Mol. Med., 2003, 75, 607-618.
47. Gautam, A.; Waldrep, J.C.; Orson, F.M.; Kinsey, B.M.; Xu, B.; Densmore, C.L: Topical gene therapy for pulmonary diseases with PEI-DNA aerosol complexes. Methods Mol. Med., 2003, 75, 561-572.
48. Davies, J.C.; Alton, E.W. Airway gene therapy. Adv. Genet., 2005, 54, 291-314. (Pubitemid 43580694)
49. Davis, J.N.; Stagg, D. Interrelationships of the volume and time components of individual breaths in resting man. J. Physiol., 1975, 245(2), 481-498.
50. Anderson, M.; Svartengren, M.; Bylin, G.; Philipson, K.; Camner, P. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am. Rev. Respir. Dis., 1993, 147(3), 524-528. (Pubitemid 23072636)
51. Bothra, M.; Lodha, R.; Kabra, S.K. Tobramycin for the treatment of bacterial pneumonia in children. Expert Opin. Pharmacother., 2012, 13(4), 565-571.
52. Zarogoulidis, P.; Papanas, N.; Kouliatsis, G.; Spyratos, D.; Zaro-goulidis, K.; Maltezos, E. Inhaled insulin: too soon to be forgotten? J. Aerosol Med. Pulm. Drug Deliv., 2011, 24(5), 213-223.
53. Zarogoulidis, P.; Kioumis, I.; Ritzoulis, C.; Petridis, D.; Darwiche, K.; Porpodis, K.; Spyratos, D.; Parrish, S.; Browning, R.; Li, Q.; Turner, J.F.; Freitag, L.; Zarogoulidis, K. New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftaz-idime, cefepime and piperacillin- tazobactam. Int. J. Pharm., 2013, 455(1-2), 182-8.
54. Ilowite, J.S.; Gorvoy, J.D.; Smaldone, G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis., 1987, 136(6), 1445-1449. (Pubitemid 18030280)
55. Dolovich, M.B.; Killian, D.; Wolff, R.K.; Obminski, G.; Newhouse, M.T. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am. Rev. Respir. Dis., 1977, 115(3), 397-402. (Pubitemid 8064142)
56. Dolovich, M.B.; Sanchis, J.; Rossman, C.; Newhouse, M.T. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J. Appl. Physiol., 1976, 40(3), 468-471.
57. Dolovich, M.; Ryan, G.; Newhouse, M.T. Aerosol penetration into the lung; influence on airway responses. Chest, 1981, 80(6 Suppl), 834-836. (Pubitemid 12222774)
58. Sanchis, J.; Dolovich, M.; Rossman, C.; Newhouse, M. Lung clearance in patients with airways obstruction. Bull. Physiopathol. Respir. (Nancy), 1973, 9(2), 325-337.
59. Deffebach, M.E.; Charan, N.B.; Lakshminarayan, S.; Butler, J. The bronchial circulation. Small, but a vital attribute of the lung. Am. Rev. Respir. Dis., 1987, 135(2), 463-481. (Pubitemid 17012114)
60. Labiris, N.R.; Dolovich, M.B. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56(6), 600-612. (Pubitemid 37491711)
61. O'Callaghan, C.; Barry, P.W. The science of nebulised drug delivery. Thorax, 1997, 52(Suppl 2), S31-44. (Pubitemid 27239451)
62. Hess, D.R. Nebulizers. principles and performance. Respir. Care, 2000, 45(6), 609-622.
63. Ari, A.; Areabi, H.; Fink, J.B. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir. Care, 2010, 55(7), 837-844.
64. Dhand, R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care, 2002, 47(12), 1406-1416; discussion 1416-1408.
65. Waldrep, J.C.; Dhand, R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr. Drug Deliv., 2008, 5(2), 114-119. (Pubitemid 351536317)
66. Abu-Rabie, P.; Denniff, P.; Spooner, N.; Brynjolffssen, J.; Gal-luzzo, P.; Sanders, G. Method of applying internal standard to dried matrix spot samples for use in quantitative bioanalysis. Anal. Chem., 2011, 83(22), 8779-8786.
67. Koshkina, N.V.; Knight, V.; Gilbert, B.E.; Golunski, E.; Roberts, L.; Waldrep, J.C. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother. Pharmacol., 2001, 47(5), 451-456. (Pubitemid 32397623)
68. 2 enriched air inhalation paradigm. Biol. Psychol., 1998, 49(1-2), 109-122. (Pubitemid 28479802)
69. Zierenberg, B. Optimizing the in vitro performance of Respimat. J. Aerosol. Med., 1999, 12(Suppl 1), S19-24. (Pubitemid 29471418)
70. Newman, S.P.; Brown, J.; Steed, K.P.; Reader, S.J.; Kladders, H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest, 1998, 113, (4), 957-963. (Pubitemid 28216438)
71. Bateman, E.D.; Tashkin, D.; Siafakas, N.; Dahl, R.; Towse, L.; Massey, D.; Pavia, D.; Zhong, N.S. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med, 2010, 104, (10), 1460-1472.
72. Dolovich, M. New propellant-free technologies under investigation. J. Aerosol Med., 1999, 12(Suppl 1), S9-17.
73. Newman, S.P.; Moren, F.; Trofast, E.; Talaee, N.; Clarke, S.W. Deposition and clinical efficacy of terbutaline sulphate from Tur-buhaler, a new multi-dose powder inhaler. Eur. Respir. J., 1989, 2, (3), 247-252. (Pubitemid 19107106)
74. Borgstrom, L.; Bondesson, E.; Moren, F.; Trofast, E.; Newman, S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J., 1994, 7(1), 69-73. (Pubitemid 24075127)
75. United Nations Environment Programme. Ozone Secretariat. Handbook for the Montreal Protocol on Substances that Deplete the Ozone Layer. 3rd. ed. Ozone Secretariat: Nairobi, 1993.
76. Crompton, G.K. Problems patients have using pressurized aerosol inhalers. Eur. J. Respir. Dis. Suppl., 1982, 119, 101-104. (Pubitemid 12060363)
77. Newman, S.P.; Pavia, D.; Moren, F.; Sheahan, N.F.; Clarke, S.W. Deposition of pressurised aerosols in the human respiratory tract. Thorax, 1981, 36(1), 52-55. (Pubitemid 11188675)
78. Bennett, W.D.; Smaldone, G.C. Human variation in the peripheral air-space deposition of inhaled particles. J. Appl. Physiol., 1987, 62(4), 1603-1610. (Pubitemid 17070447)
79. Dolovich, M.; Ruffin, R.; Corr, D.; Newhouse, M.T. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest, 1983, 84(1), 36-41. (Pubitemid 13073618)
80. Newman, S.P.; Weisz, A.W.; Talaee, N.; Clarke, S.W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax, 1991, 46(10), 712-716.
81. Martin, R.J.; Szefler, S.J.; Chinchilli, V.M.; Kraft, M.; Dolovich, M.; Boushey, H.A.; Cherniack, R.M.; Craig, T.J.; Drazen, J.M.; Fagan, J.K.; Fahy, J.V.; Fish, J.E.; Ford, J.G.; Israel, E.; Kunsel-man, S.J.; Lazarus, S.C.; Lemanske, R.F., Jr.; Peters, S.P.; Sork-ness, C.A. Systemic effect comparisons of six inhaled corticoster-oid preparations. Am. J. Respir. Crit. Care Med., 2002, 165(10), 1377-1383. (Pubitemid 34522940)
82. Wilson, A.M.; Dempsey, O.J.; Coutie, W.J.; Sims, E.J.; Lipworth, B.J. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet, 1999, 353(9170), 2128. (Pubitemid 29278488)
83. Kendrick, A.H.; Smith, E.C.; Wilson, R.S. Selecting and using nebuliser equipment. Thorax, 1997, 52(Suppl 2), S92-101.
84. Loffert, D.T.; Ikle, D.; Nelson, H.S. A comparison of commercial jet nebulizers. Chest, 1994, 106(6), 1788-1792.
85. Hess, D.; Fisher, D.; Williams, P.; Pooler, S.; Kacmarek, R.M. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest, 1996, 110(2), 498-505. (Pubitemid 26269284)
86. Johnson, M.A.; Newman, S.P.; Bloom, R.; Talaee, N.; Clarke, S.W. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. Chest, 1989, 96(1), 6-10. (Pubitemid 19176405)
87. Newman, S.P.; Pellow, P.G.; Clay, M.M.; Clarke, S.W. Evaluation of jet nebulisers for use with gentamicin solution. Thorax, 1985, 40(9), 671-676. (Pubitemid 15229602)
88. Faurisson, F.; Dessanges, J.F.; Grimfeld, A.; Beaulieu, R.; Kitzis, M.D.; Peytavin, G.; Lefebvre, J.P.; Farinotti, R.; Sautegeau, A. Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose. Respiration, 1995, 62(Suppl 1), 13-18.
89. Jenkins, M. Clinical evaluation of CFC-free metered dose inhalers. J. Aerosol Med., 1995, 8(Suppl 1), S41-47.
90. Parameswaran, K.N.; Inman, M.D.; Ekholm, B.P.; Morris, M.M.; Summers, E.; O'Byrne, P.M.; Hargreave, F.E. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am. J. Respir. Crit. Care Med., 1999, 160(1), 354-357. (Pubitemid 29326113)
91. Leach, C.L. Improved delivery of inhaled steroids to the large and small airways. Respir. Med., 1998, 92(Suppl A), 3-8.
92. Davies, R.J.; Stampone, P.; O'Connor, B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir. Med., 1998, 92(Suppl A), 23-31.
93. Rogers, D.F.; Ganderton, D. Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at Royal Brompton National Heart & Lung Institute, London 24 June 1994. Respir. Med., 1995, 89(4), 253-261.
94. Lei, P.; Girshick, S.L. PEGylation of gold-decorated silica nanoparticles in the aerosol phase. Nanotechnology, 2013, 24(33), 335602.
95. Leclerc, J.; Courcot-Ngoubo Ngangue, E.; Cauffiez, C.; Allorge, D.; Pottier, N.; Lafitte, J.J.; Debaert, M.; Jaillard, S.; Broly, F.; Lo-Guidice, J.M. Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie, 2011, 93(6), 1012-1027.
96. Bosquillon, C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci., 2010, 99(5), 2240-2255.
97. Zarogoulidis, P.; Papanas, N.; Kouliatsis, G.; Spyratos, D.; Zaro-goulidis, K.; Maltezos, E. Inhaled insulin: too soon to be forgotten? J. Aerosol. Med. Pulm. Drug Deliv., 2011, 24(5), 213-223.
98. Zarogoulidis, P.; Petridis, D.; Ritzoulis, C.; Darwiche, K.; Spyra-tos, D.; Huang, H.; Goldberg, E.P.; Yarmus, L.; Li, Q.; Freitag, L.; Zarogoulidis, K. Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: Back to drawing the residual cup. Int. J. Pharm., 2013, 453(2), 480-487.
99. Zarogoulidis, P.; Chatzaki, E.; Porpodis, K.; Domvri, K.; Hohen-forst-Schmidt, W.; Goldberg, E.P.; Karamanos, N.; Zarogoulidis, K. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomedicine, 2012, 7, 1551-1572.
100. Zarogoulidis, P.; Giraleli, C.; Karamanos, N.K. Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered. Ther. Deliv., 2012, 3(9), 1021-1023.
101. Zarogoulidis, P.; Eleftheriadou, E.; Sapardanis, I.; Zarogoulidou, V.; Lithoxopoulou, H.; Kontakiotis, T.; Karamanos, N.; Zachari-adis, G.; Mabroudi, M.; Zisimopoulos, A.; Zarogoulidis, K. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. New Drugs, 2012, 30(4), 1628-1640.
102. Zarogoulidis, P.; Darwiche, K.; Hohenforst-Schmidt, W.; Huang, H.; Li, Q.; Freitag, L.; Zarogoulidis, K. Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotech-nology in the management of lung cancer. Future Oncol., 2013, 9(8), 1171-1194.
103. Zarogoulidis, P.; Hohenforst-Schmidt, W.; Darwiche, K.; Krauss, L.; Sparopoulou, D.; Sakkas, L.; Gschwendtner, A.; Huang, H.; Turner, F.J.; Freitag, L.; Zarogoulidis, K. 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy. Gene Ther., 2013, 20(10), 1022-8.
104. Zarogoulidis, P.; Karamanos, N.K.; Porpodis, K.; Domvri, K.; Huang, H.; Hohenforst-Schmidt, W.; Goldberg, E.P.; Zarogoulidis, K., Zarogouldis, P. et al. Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotech-nology. Int. J. Mol. Sci., 2012, 13, 10828-10862. Int. J. Mol. Sci., 2012, 13(12), 17290-17291.
105. Zarogoulidis, P.; Kontakiotis, T.; Zarogoulidis, K. Inhaled gene therapy in lung cancer: "as for the future, our task is not to foresee it, but to enable it". Ther. Deliv., 2012, 3(8), 919-921.
106. Schlenk, F.; Grund, S.; Fischer, D. Recent developments and perspectives on gene therapy using synthetic vectors. Ther. Deliv., 2013, 4(1), 95-113.